All In Biotech

Drug Trial Radar · NCT02671435

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 383 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

383

Actual

Start

Feb 22, 2016

Primary completion

Oct 26, 2021

Study completion Jul 30, 2027

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

Conditions

  • Advanced Solid Tumors

Interventions

  • MonalizumabDrug

    Participants will receive IV infusion of monalizumab as stated in arm description.

  • DurvalumabDrug

    Participants will receive IV infusion of durvalumab as stated in arm description.

  • CetuximabDrug

    Participants will receive IV infusion of cetuximab as stated in arm description.

  • mFOLFOX6Drug

    Participants will receive IV infusion of mFOLFOX as stated in arm description.

  • BevacizumabDrug

    Participants will receive IV infusion of bevacizumab as stated in arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 through 246.9 weeks (maximum observed duration)
  2. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  3. Change From Baseline in Respiratory Rate (RR)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  4. Change From Baseline in Pulse Rate (PR)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  5. Change From Baseline in Body Temperature (BT)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  6. Change From Baseline in Oxygen Saturation (OS)Time frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  7. Number of Participants With Notable Change in QTcF and QTcB From BaselineTime frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  8. Number of Participants With at Least 2-Grade Shift From Baseline in Laboratory ParametersTime frame: Day 1 (baseline) through 246.9 weeks (maximum observed duration)
  9. Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Day 1 to 28 days after the first dose of study drugs
  10. Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1BTime frame: Baseline (Days -28 to -1) through 54.8 months (maximum observed duration)

Locations

49 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Duarte, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    Santa Monica, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Tampa, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    New Brunswick, New Jersey

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Providence, Rhode Island

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Blacktown, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Marseille, France

  • Research Site

    Nantes, France

  • Research Site

    Debrecen, Hungary

  • Research Site

    Milan, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Grafton, New Zealand

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.